Screener
Harmony Biosciences Holdings, Inc. HRMY Investment and other (expense) income, net
Investment and other (expense) income, net at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Harmony Biosciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNonoperating.
The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:16 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056720
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating income | 37,291 | 56,245 |
| Other expense, net | (127) | (276) |
| Interest expense | (3,234) | (3,836) |
| Interest income | 5,757 | 5,044 |
| Income before income taxes | 39,687 | 57,177 |
| Income tax expense | (7,199) | (11,617) |
| Net income | $32,488 | $45,560 |
| Unrealized (loss) income on investments | (759) | 179 |
Item 1. Financial Statements
FAQ
- What is Harmony Biosciences Holdings, Inc.'s investment and other (expense) income, net?
- Harmony Biosciences Holdings, Inc. (HRMY) reported investment and other (expense) income, net of $5.76M in Q1 2026.
- How has Harmony Biosciences Holdings, Inc.'s investment and other (expense) income, net changed year-over-year?
- Harmony Biosciences Holdings, Inc.'s investment and other (expense) income, net increased by 14.1% year-over-year, from $5.04M to $5.76M.
- What is the long-term trend for Harmony Biosciences Holdings, Inc.'s investment and other (expense) income, net?
- Over 4 years (2021 to 2025), Harmony Biosciences Holdings, Inc.'s investment and other (expense) income, net has grown at a 214.5% compound annual growth rate (CAGR), from $224K to $21.92M.
- What does investment and other (expense) income, net mean?
- This metric represents the net financial result of non-operating activities, including interest income earned on cash balances and investment returns, offset by interest expenses or other non-core financial costs. It provides insight into how a company manages its excess liquidity and capital structure outside of its primary pharmaceutical operations. Investors use this to assess the impact of treasury management and debt servicing on the company's overall bottom line.
Ask your AI about Harmony Biosciences Holdings, Inc.'s investment and other (expense) income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude